运用中药周期方法治疗冲任失调型女性黄褐斑的临床研究论文外文翻译中英文论文对照翻译.docx

运用中药周期方法治疗冲任失调型女性黄褐斑的临床研究论文外文翻译中英文论文对照翻译.docx

《运用中药周期方法治疗冲任失调型女性黄褐斑的临床研究论文外文翻译中英文论文对照翻译.docx》由会员分享，可在线阅读，更多相关《运用中药周期方法治疗冲任失调型女性黄褐斑的临床研究论文外文翻译中英文论文对照翻译.docx（19页珍藏版）》请在冰点文库上搜索。

运用中药周期方法治疗冲任失调型女性黄褐斑的临床研究论文外文翻译中英文论文对照翻译

第一部位英文论文

题目：

运用中药周期方法治疗冲任失调型女性黄褐斑的临床研究

TheuseoftraditionalChinesemedicine-cycleapproachtothetreatmentoftheclinicalstudyofChongandRendisordersfemalemelasma

[Abstract]ObjectiveToinvestigatetheuseoftraditionalChinesemedicinecycletherapyadjustmentredanytheoffsettypefemalemelasmaclinicalefficacy.StrictlyinaccordancewiththecriteriaestablishedbyChongandRendisordersfemalechloasma60patientswererandomlydividedintotwogroups:

thetreatmentgroup30casesinthecontrolgroupof30patients.cycleapproachofChinesemedicineinthetreatmentChongandRendisorderstypemelasmatreatmentgrouptakingwesternmedicinetranexamicacidasacontrolgroupweretreatedfor3months.Observationofpatientsbeforeandafterlesionarea,skinlesions,colorandchangesinreproductivehormones.Results

（1）Aftertreatmentefficacytotalefficiencywas86.7%and63.3%,traditionalChinesemedicinegroupwasbetterthanthecontrolgrouptranexamicacid,andthedifferencewasstatisticallysignificance（P<0.05）.

（2）TCMgroupaftertreatment,estradiol（E2）andfollicle-stimulatinghormone（FSH）（P<0.01）lower,betterthanthetranexamicacidgroup.（3）Chinesemedicinecycleapproachinthetreatmentofimprovemelasmapatientsavarietyofclinicalsymptoms,thetreatmentgroupthanthecontrolgroupchloasmasize,pigmentimprovementthetheconclusiontwodrugsmelasmaconditionhasimprovedtosomeextent,butthetreatmentgroup,thetotalefficiencyissignificantlybetterthanthecontrolgroup,andwithlowerestradiol（E2）,promotetheroleoffolliclestimulatinghormone（FSH）content.traditionalChinesemedicineartificialcycleapproachtothetreatmentofchloasmabetter.

[Keywords]Chinesemedicinecycletherapy;femalechloasma;clinicalresearch;titlesofpapers

[Abstract]ObjectiveToobservetheuseofsuchmethodsasChinesemedicinecycletherapyadjustmentfemalechloasmawithdisharmonyofthoroughfareandconceptionvessels.MethodsInstrictaccordancewiththeformulationofinclusioncriteriachoosebluntasfemalechloasmawithdisharmonyofthoroughfareandconceptionvessels,60casespatientswererandomlydividedintotwogroups:

treatmentgroup,30cases.WithChinesemedicinecycletherapywasasdisharmonyofthoroughfareandconceptionvesselschloasmaastreatmentgroup,totaketranexamicacidascontrolgroup.Twogroupsoftreatmentwerefor3months.Thepatientswereobservedbeforeandafterthetreatmentoflesionsarea,colorandreproductivehormonechanges.ResultsThetwogroupsoftotaleffectiveratewere86.7%and63.3%,respectively,tranexamicacidcontrolgroupwashigherthantheammonia,andthedifferencewasstatisticallysignificant（P<0.05）.InChinesemedicinesgroupaftertreating,estradiol（E2）,follicle-stimulatinghormone（FSH）reduced（P<0.01）,theeffectisbetterthanthatofammoniatranexamicacidgroup.Chinesemedicinetreatmentcanimproveclinicalsymptomsinpatientswithmelasma.Size,degreeofimprovementinpigmentinmelasmatreatmentgroupwasbetterthanthecontrolgroup.ConclusionTwogroupsofdrugsonchloasmaconditionhaveimproved,butthetotaleffectiverateintreatmentgroupwasbetterthancontrol,andhasreducedestradiol（E2）,follicle-stimulatinghormone（FSH）levelsoffunction.ThatTCMartificiallycycletherapyonchloasmahasbettercurativeeffect.

[Keywords:

]TCMcycletherapy;femalechloasma;clinicalresearch

Melasmaiscausedbyavarietyoffactors,limitations,andacquiredskinpigmentation.Clinicalmanifestationsoffacialsymmetrydistribution,clearboundarybrownpatches.Manygoodhairinyoungwomen,waschronicdiseaseAlthoughtherewerenosymptoms,butseriousimpactonpatientswithfacialbeauty,spiritandlifetobringalotoftroubleandpain,andevencausephysicalandpsychologicalbarrierswithahighincidenceofthedisease,andeasydiagnosisofrefractory.

Thechloasmaetiologyisverycomplex,modernmedicalresearchthatthechloasmaandendocrinedisorders,pregnancy,oralcontraceptives,uterine,ovariandisease,sunlightandotherfactors.Majorityofscholarsbelievethattheincidenceofendocrinedysfunctioninfemalepatientswithmelasmahypothalamic-pituitary-ovarianaxisimbalancesignificantrelationship,sothetreatmentofmultiplestartfromendocrineadjustmentandthemotherlandmedicineMelasmaisanexternallocalmanifestationsofthediseaselocatedintheskin,includingthecauseofdysfunctionalorgansinthebody,shouldbetakenOuterdiseaseGovernance"method[1].

Throughthelong-termtreatmentofmelasma,combinedwithyearsofclinicalexperience,andinalargenumberofpreliminarystudiesonthebasisofthatpartofthefemalemelasmaiscausedbecauseofChongandRendisordersusingChinesemedicineartificialcycleapproachinthetreatmentofbasalbodytemperaturebyChongandRendisorderstypechloasma,effective,safe,easytorelapse,aremoresatisfiedwiththisstudy,theuseoftraditionalChinesemedicineartificialcycletreatmentofmelasmaandcontroltodowithWesternmedicinetranexamicacidtreatmentgroup,byobservingtheclinicalefficacyandserumlevelsofsexhormones,furthertounderstandtherelationshipoffemalechloasmaEndocrineartificialcycleapproachtoexploretraditionalChinesemedicinetreatmentofmelasmamechanism.

ThisJanuarytoDecember2009,duringtheThirdAffiliatedHospitalofZhejiangUniversityofTraditionalChineseMedicine,dermatologyclinic,clinicaldiagnosischloasma,TCMChongandRendisorders60patients,dividedintoatreatmentgroupandacontrolgroup,anditsefficacyanalysisandcomparisonareasfollows.

1MaterialsandMethods

1.1GeneralInformation

1.1.1CaseSource

60patientswereenrolledfortheperiodJanuarytoDecember2009,theThirdAffiliatedHospitalofZhejiangUniversityofTraditionalChineseMedicine,Dermatologyoutpatienttreatmentoffemalepatients.Chloasmaallincompliancewiththediagnosticcriteria.

1.1.2StandardsofMedicalCare

1.1.2.1diagnosticcriteria

ReferenceIntegrativeMedicineInstituteofDermatologyandVenereologyProfessionalCommitteepigmentdiseasestudygroupenactedinDecember2003<>"develop[2].

Westerndiagnosticcriteria:

（1）thefaceclearpatchesoflightbrowntodarkbrownincolorboundaries,usuallysymmetricallydistributed,inflammationandscaly.

（2）noobvioussymptoms.Femalemultiple（3）occursmainlyafterpuberty.（4）Theconditioncanbecertainseasonal,normallythesummerheavywinterlight.（5）excludepigmentationcausedbyotherdiseases（suchaszygomaticbrownbluenevusofRiehlmelanosisandpigmentedactiniclichenplanus）.

1.1.2.2inclusioncriteria

>><

（1）causesrelatedtopregnancy

（2）associatedwithirregularmenstruation（menstruallatemenstruationhasnotregularly,afterafewmonths,amenorrhea）and（3）thefullrangeofabnormaltocheckserumreproductivehormone.（4）afterthefirsttwomilkforinflation,temperamentirritability,restlessness（5）beforetheheadache.（6）premenstrualinsomnia（7）purpletonguedarkecchymosis（8）pulsestringorastringent.

WherehavetheabovefourrecognizableChongandRendisorderstypefacialmelasma.

1.1.2.3efficacycriteria[2]

Basiccure:

thenakedeye,asthestainareasubsidedby>90%,thecolordisappeared;ratedbasis,decreasedaftertreatmentindex>=0.8.Markedly:

thenakedeye,asthestainareasubsidedby>60%,thecolorfadessignificantly;scoringcalculationdecreasedaftertreatmentindex>=0.5.improved:

thenakedeye,asthestainareasubsidedby>30%,thecolorfades;ratedbasis,decreasedaftertreatmentindex>=0.3.invalid:

<30%regressionofthenakedeye,asthestainarea,colorchangesTheobvious;ratedbasis,decreasedaftertreatmentindex>=0.

1.1.2.4Ratedmethodsandstandards

（1）lesionsareascore:

0fornolesions;1area<2cm2;area2~4cm2;the3lesionarea>4cm2

（2）lesionscolorscore:

0fornormalskincolor;1Hazel;2brown;3darkbrown（3）totalscore=theareascore+colorscore（4）scoringdeclineintheindexcalculationmethod:

thedecliningindex=（totalscorebeforetreatment-totalpointsaftertreatment）/treatmentbeforethetotalscore.

1.1.3groupingmethod

Principlerandomizedcontrolpacket.60wererandomlydividedintoatreatmentgroupandammoniatranexamicacidcontrolgroup.Treatmentgroupof30patients,aged28to51yearsofage,durationof0.25to21years;30patients,ages29to50yearsofage,durationof0.3to15years.

1.2Treatment

1.2.1treatmentgroup

（1）usedrugs,thetreatmentgroup（basalbodytemperature,periodicuseoftraditionalChinesemedicinetreatment.）①ThemenstruallatefollicularphasetogethertheArtemisiaannuaturtleDecoctionLiuWeiDiHuangTang

（2）betweenperiods（ovulation）topromoteovulationTongaLess.③premenstrual（lutealphase）ImmortalssouptogetherJinkuishenqiwan,additionandsubtraction④menstrualperiodTaohongsiwusoupandsubtraction.

（2）MethodofAdministration:

fryaliquidof200ml,oral,twicedaily,riceafterthetaking.

1.2.2controlgroup

（1）controlgroupthemedicationusedrugs:

tranexamicacidtablets（tradename:

properlyrace-sensitive;factoryname:

DALLCHISANKYOPROPHARMACO.,LTD,ShizuokaPlant;specifications:

0.5g/piece）

（2）:

0.25g,orally,tid.

1.2.3treatment

Treatmentwithoutotherdrugsduringthreemenstrualcyclesforacourseoftreatment,efficacywasevaluatedafteracourseoftreatment.

1.2.4Laboratoryindicators

Pati